<DOC>
	<DOCNO>NCT01772472</DOCNO>
	<brief_summary>This 2-arm , randomize , open-label study evaluate efficacy safety trastuzumab emtansine versus trastuzumab adjuvant therapy patient HER2-positive breast cancer residual tumor present breast axillary lymph node follow preoperative therapy . Eligible patient randomize receive either trastuzumab emtansine 3.6 mg/kg trastuzumab 6 mg/kg intravenously every 3 week 14 cycle . Radiotherapy and/or hormone therapy give addition indicate .</brief_summary>
	<brief_title>A Study Trastuzumab Emtansine Versus Trastuzumab Adjuvant Therapy Patients With HER2-Positive Breast Cancer Who Have Residual Tumor Breast Axillary Lymph Nodes Following Preoperative Therapy ( KATHERINE )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasm , Residual</mesh_term>
	<mesh_term>Ado-trastuzumab emtansine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Maytansine</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age HER2positive breast cancer Histologically confirm invasive breast carcinoma Clinical stage T14/N03/M0 presentation ( patient T1a/bN0 tumor eligible ) Completion preoperative systemic chemotherapy HER2directed treatment consist least 6 cycle chemotherapy total duration least 16 week , include least 9 week trastuzumab least 9 week taxanebased therapy Adequate excision : surgical removal clinically evident disease breast lymph node specify protocol Pathological evidence residual invasive carcinoma breast axillary lymph node follow completion preoperative therapy An interval 12 week date surgery date randomization Known hormonereceptor status Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Adequate hematologic , renal liver function Screening Left ventricular ejection fraction ( LVEF ) &gt; /= 50 % echocardiogram ( ECHO ) multiplegated acquisition ( MUGA ) receive neoadjuvant chemotherapy decrease LVEF 15 % absolute point prechemotherapy LVEF . Or , prechemotherapy LVEF assess , screen LVEF must &gt; /= 55 % completion neoadjuvant chemotherapy . For woman postmenopausal surgically sterile : agreement remain abstinent use single combine contraceptive method result failure rate &lt; 1 % per year treatment period least 7 month last dose study drug Documentation hepatitis B virus hepatitis C virus serology require Stage IV ( metastatic ) breast cancer History prior ( ipsi contralateral breast cancer except lobular carcinoma situ Evidence clinically evident gross residual recurrent disease follow preoperative therapy surgery Progressive disease preoperative systemic therapy Treatment anticancer investigational drug within 28 day prior commence study treatment History malignancy within last 5 year except appropriately treat carcinoma situ cervix , nonmelanoma skin carcinoma , Stage I uterine cancer , nonbreast malignancy similar outcome mention Patients radiotherapy would recommend breast cancer treatment contraindicate medical reason Current NCI CTCAE ( Version 4.0 ) Grade &gt; /= 2 peripheral neuropathy History exposure follow cumulative dos anthracyclines : Doxorubicin &gt; 240 mg/m2 ; Epirubicin Liposomal DoxorubicinHydrochloride ( MyocetÂ® ) &gt; 480 mg/m2 ; For anthracyclines , exposure equivalent doxorubicin &gt; 240 mg/m2 Cardiopulmonary dysfunction define protocol Prior treatment trastuzumab emtansine Current severe , uncontrolled systemic disease Pregnant lactate woman Any known active liver disease , e.g . due HBV , HCV , autoimmune hepatic disorder , sclerosing cholangitis Concurrent serious uncontrolled infection require treatment know infection HIV History intolerance , include Grade 3 4 infusion reaction hypersensitivity trastuzumab murine protein component product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>